METASTATIC PROSTATE CARCINOMA

This study looks at whether men with metastatic prostate cancer that responds extremely well to hormone therapy can safely take a break from treatment. The goal is to see if their testosterone levels can recover and how long they can stay off therapy without the cancer worsening.…

This early-phase trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the cancer. About 65 adults wi…

This study tests a combination of two drugs—cabazitaxel (a chemotherapy) and enzalutamide (a hormone blocker)—in men with prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the safest dose and see if the combo can lower PSA lev…

This study tests whether adding cediranib to olaparib works better than olaparib alone for men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. About 90 men will take part. The goal is to see if the combination slows cancer growth…

This phase 2 trial tests a combination of abiraterone, prednisone, and apalutamide in 60 men with hormone-naive prostate cancer that has spread. The goal is to see how long patients can stay on treatment and how well it controls the cancer. Participants must have high-risk featur…

This study tests different combinations of approved drugs to treat men with advanced prostate cancer that has spread and no longer responds to hormone therapy. About 196 men will receive either a standard hormone-blocking combo or that combo plus an immunotherapy or chemotherapy …

This study tests three treatment options for men with advanced prostate cancer that has stopped responding to hormone therapy and has specific DNA repair defects. Participants receive either abiraterone (a hormone-blocking drug), olaparib (a targeted drug), or both together. The …

This study tests a combination of three drugs (apalutamide, abiraterone, and prednisone) given after chemotherapy for men with advanced prostate cancer that has spread and hasn't been treated before. The goal is to see if this approach can lower PSA levels more effectively and al…

This study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other drugs and radiation in people with advanced cancers that have not responded to standard treatments. About 173 adults with various solid tumors, including prostate cancer, will re…

This study tests a new drug (berzosertib) combined with standard chemotherapy (carboplatin) in men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if this combination shrinks tumors or lowers PSA l…

This study tests a two-step treatment for men with an aggressive form of prostate cancer that has spread. First, patients get chemotherapy plus an immunotherapy drug. Then, they take a maintenance pill (niraparib) either alone or with more immunotherapy. The goal is to see if thi…

This early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…

This study collects tissue, blood, and urine samples from 92 men with prostate cancer that has spread. Researchers look for gene changes that might explain how well the cancer responds to standard hormone therapy. The goal is to find biomarkers, not to test a new treatment.

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. The goal is to track how cancer changes over time and during treatment. Researchers hope this will help them understand why some cancers resist therapy a…

This study looks at how certain hormone therapies for advanced prostate cancer affect men's thinking skills, like memory and concentration. Researchers will use brain scans and thinking tests to see if these treatments cause changes in the brain. The goal is to understand why som…